Mylan, a global pharmaceutical company, is introducing two new HIV treatments, Symfi Lo and Cimduo, it was reported yesterday.

The products were approved last month by the US Food and Drug Administration (FDA). Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) 400 mg/300 mg/300 mg tablets is a once-daily, single-tablet regimen and is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and paediatric patients weighing at least 35 kg. Cimduo (lamivudine and tenofovir disoproxil fumarate) 300 mg/300 mg tablets is a once-daily combination of two nucleo(t)side reverse transcriptase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and paediatric patients weighing at least 35 kg.

The company anticipates launching Symfi Lo in the coming weeks and Cimduo in the second quarter of 2018. These upcoming launches will extend the company's global antiretroviral platform and are intended to help address the high cost of HIV treatment in the United States. Total spending for HIV medications in the United States exceeds USD20bn per annum, and HIV is a top cost driver for many healthcare payers.